How do you manage severe lenalidomide-associated drug rash in a transplant-eligible patient with multiple myeloma?

Would your approach change based on the type of reaction (eg. Stevens-Johnson syndrome vs DRESS)?

How would you address maintenance (if any) post-transplant?

Would you consider pomalidomide for use in future lines of therapy?

Answer from: Medical Oncologist at Community Practice

A rash with lenalidomide occurs in up to a third of patients exposed, and it's likely that dose corresponds directly with rash severity. While excellent desensitization protocols appear effective (PMID 31400463), most of us want to be able to deal with this with a phone call or text message that inc...

Please select the option that best describes you:

How do you manage severe lenalidomide-associated drug rash in a transplant-eligible patient with multiple myeloma?

Related Questions